[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse UBE2J2

Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass type IV membrane protein
Domain PF00179 Ubiquitin-conjugating enzyme
Function

Catalyzes the covalent attachment of ubiquitin to other proteins. Seems to function in the selective degradation of misfolded membrane proteins from the endoplasmic reticulum (ERAD).

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0006626 protein targeting to mitochondrion
GO:0006839 mitochondrial transport
GO:0006986 response to unfolded protein
GO:0010498 proteasomal protein catabolic process
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0036503 ERAD pathway
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0051222 positive regulation of protein transport
GO:0070585 protein localization to mitochondrion
GO:0072655 establishment of protein localization to mitochondrion
GO:0090316 positive regulation of intracellular protein transport
GO:1903214 regulation of protein targeting to mitochondrion
GO:1903533 regulation of protein targeting
GO:1903747 regulation of establishment of protein localization to mitochondrion
GO:1903749 positive regulation of establishment of protein localization to mitochondrion
GO:1903829 positive regulation of cellular protein localization
GO:1903955 positive regulation of protein targeting to mitochondrion
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0061630 ubiquitin protein ligase activity
GO:0061631 ubiquitin conjugating enzyme activity
GO:0061650 ubiquitin-like protein conjugating enzyme activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component GO:0000151 ubiquitin ligase complex
> KEGG and Reactome Pathway
 
KEGG hsa04120 Ubiquitin mediated proteolysis
hsa04141 Protein processing in endoplasmic reticulum
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UBE2J2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UBE2J2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.42; FDR: 0.04180 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UBE2J2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2150.42
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1520.945
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.260.871
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2650.534
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0060.997
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6010.786
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0020.996
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1070.936
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.090.953
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2620.864
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4380.848
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0820.116
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UBE2J2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBE2J2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBE2J2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBE2J2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBE2J2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UBE2J2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UBE2J2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUBE2J2
Nameubiquitin-conjugating enzyme E2, J2
Aliases NCUBE2; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast); NCUBE-2; PRO2121; non-canonical ubiquitin ......
Chromosomal Location1p36.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UBE2J2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.